Former Novartis exec joins Genmab

Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer.

Based out of the biotech's Princeton, US office, Dr Klimovsky will be responsible for the company's global product development strategy.

She joins Genmab from Novartis, where she most recently served as senior vice president and global head of oncology clinical development, having previously served as head of the global programme for cancer drug Afinitor.

Prior to this, Dr Klimovsky held director-level positions at Merck & Co in the US, and Bristol-Myers Squibb in South America.

Jan van de Winkel, Genmab's chief executive, said: “We are very pleased to welcome Judith to Genmab.

“She has a strong track record and skills in cancer drug development which will further strengthen the company as we build a winning team to continue our success in the future on the road to becoming a sustainably profitable biotech company.

“With Judith heading our product development efforts we will be able to bring forward truly differentiated products that have the potential to transform the treatment of cancer and provide great benefits to patients and their families in the future.”